Title
Allogenic Cord Blood Transfusion in Patients With Cerebral Palsy
Efficiency Evaluation of Allogenic Umbilical Cord Blood Mononuclear Cells (UCB-MNC) Transfusion in Patients With Autism
Phase
Phase 2Lead Sponsor
Medical Centre DinastyStudy Type
InterventionalStatus
RecruitingIndication/Condition
Cerebral PalsyIntervention/Treatment
CP CB-MNC injection ...Study Participants
40Cerebral palsy is a disorder of movement and posture resulted from a non-progressive lesion or injury of the immature brain. It is a leading cause of childhood onset disability.
Many experimental animal studies have revealed that umbilical cord blood is useful to repair neurological injury in brain.
On the basis of many experimental studies, umbilical cord blood is suggested as a potential therapy for cerebral palsy.
Cerebral palsy (CP) is a group of neurodevelopmental conditions with abnormal movement and posture resulted from a non-progressive cerebral disturbance. It is the most common cause of motor disability in childhood. Most therapies are palliative rather than restorative. Umbilical cord blood (UCB) may be used as restorative approach for children with CP.
Many experimental animal studies have revealed that UCB is beneficial to improve and repair neurological injuries, this effect achieved due to immune regulation and angiogenesis as well as the neuroprotective effect.
Based on animal studies and some clinical trials, UCB is suggested as a potential therapy for children with CP.
This study is prospective, non randomized (open label) with control group.
CB-MNC injection from different donors. One dose consist 20-50 mil MNC/kg.The protocol include 3 injection at monthly intervals.
The standard therapy can include drugs, special psychology training etc.
CP CB-MNC injection from different donors and standard therapy.
Inclusion Criteria: - Confirmed diagnosis: Cerebral Palsy. Exclusion Criteria: the presence of the following diseases in history: heart failure in the stage of decompensation, stroke in history less than 1 year ago, blood diseases; decompensation of chronic and endocrinological diseases; acute respiratory viral and bacterial infections, period less than 1 month after the acute phase. HIV infection, hepatitis B and C. oncological diseases, chemotherapy in the anamnesis; tuberculosis.
